Abstract: The present invention belongs to the medical field, and relates to novel ?-lactamase inhibitors, for the treatment of bacterial infections in combination with ?-lactam antibiotics, including infection caused by drug resistant organisms and especially multi-drug resistant organisms. The present invention includes compounds according to formula (I): or pharmaceutically acceptable salts thereof, wherein M and R are as defined herein.

Abstract: Disclosed are a battery module and a battery pack having the same for a vehicle. The battery module includes a cell row and output electrode connecting plates. The cell row has a first end and a second end in an arrangement direction of a plurality of cells. Each cell includes a first end cell located at the first end and a second end cell located at the second end. The output electrode connecting plates include a positive electrode connecting plate and a negative electrode connecting plate, one of which is connected to the first end cell, and the other is connected to a cell adjacent to the first end cell.

Abstract: Disclosed are a battery module and a battery pack having the same for a vehicle. The battery module includes a cell row and output electrode connecting plates. The cell row has a first end and a second end in an arrangement direction of a plurality of cells. Each cell includes a first end cell located at the first end and a second end cell located at the second end. The output electrode connecting plates include a positive electrode connecting plate and a negative electrode connecting plate, one of which is connected to the first end cell, and the other is connected to a cell adjacent to the first end cell.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: The present invention discloses a polycrystalline silicon substrate and a manufacturing method thereof. The method comprises: provide a substrate; sequentially form an amorphous silicon layer, an insulating layer and a metal catalyst layer; anneal the substrate at the first time, so that metal ions of the metal catalyst layer extend down to the amorphous silicon layer through the insulating layer, thereby inducing the amorphous silicon on the amorphous silicon layer to crystallize at the first time; remove the insulating layer and the metal catalyst layer; anneal the substrate at the second time, so that the metal ions lateral diffuse along the amorphous silicon layer, thereby inducing the amorphous silicon on the amorphous silicon layer to crystallize at the second time, forming the polycrystalline silicon layer.

Abstract: A laser crystallization system and a method of controlling crystallization energy therein are disclosed. The laser crystallization system comprises: a Mura monitor device, used for monitoring the real-time Mura status during the crystallization process; a host station, connected with the Mura monitor device, used for determining the real-time level of the real-time Mura status acquiring from the Mura monitoring device, and generating crystallization energy control order based on the real time level; a crystallization device, connected with the host station, for carrying out the crystallization energy control order generated from the host station to control the outputting crystallization energy. The Mura monitoring device is used to monitor the Mura status online in real-time, and the crystallization energy outputted by the crystallization device is controlled according to the real-time Mura status.

Abstract: The present invention discloses a polycrystalline silicon substrate and a manufacturing method thereof. The method comprises: provide a substrate; sequentially form an amorphous silicon layer, an insulating layer and a metal catalyst layer; anneal the substrate at the first time, so that metal ions of the metal catalyst layer extend down to the amorphous silicon layer through the insulating layer, thereby inducing the amorphous silicon on the amorphous silicon layer to crystallize at the first time; remove the insulating layer and the metal catalyst layer; anneal the substrate at the second time, so that the metal ions lateral diffuse along the amorphous silicon layer, thereby inducing the amorphous silicon on the amorphous silicon layer to crystallize at the second time, forming the polycrystalline silicon layer.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: Provided herein are formulations and methods for treating pain in human beings. Also provided are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both an opioid and an opioid antagonist within a single pharmaceutical dosing unit.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.

Abstract: Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are . also provided.

Abstract: Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated.